Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Population pharmacokinetics and exposure-response relationship of a muscarinic receptor antagonist, imidafenacin.

Hasegawa C, Ohno T, Nakade S, Shibakawa K, Miyabe H, Ouchi T, Ogawa M.

Drug Metab Pharmacokinet. 2013;28(3):203-12. Epub 2012 Oct 23.

2.

Population pharmacokinetic analysis of a novel muscarinic receptor antagonist, imidafenacin, in healthy volunteers and overactive bladder patients.

Ohno T, Nakade S, Nakayama K, Kitagawa J, Miyabe H, Konomi T, Miyata Y.

Drug Metab Pharmacokinet. 2008;23(6):456-63.

3.

A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder.

Homma Y, Yamaguchi O; Imidafenacin Study Group.

Int J Urol. 2009 May;16(5):499-506. doi: 10.1111/j.1442-2042.2009.02286.x. Epub 2009 Mar 29.

4.

Selective binding of bladder muscarinic receptors in relation to the pharmacokinetics of a novel antimuscarinic agent, imidafenacin, to treat overactive bladder.

Yamada S, Seki M, Ogoda M, Fukata A, Nakamura M, Ito Y.

J Pharmacol Exp Ther. 2011 Feb;336(2):365-71. doi: 10.1124/jpet.110.172288. Epub 2010 Nov 3.

5.

Long-term safety, tolerability, and efficacy of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder.

Homma Y, Yamaguchi O.

Int J Urol. 2008 Oct;15(11):986-91. doi: 10.1111/j.1442-2042.2008.02152.x. Epub 2008 Aug 28.

6.

A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder.

Homma Y, Yamaguchi T, Yamaguchi O.

Int J Urol. 2008 Sep;15(9):809-15. doi: 10.1111/j.1442-2042.2008.02104.x. Epub 2008 Jul 10.

7.

Study of the population pharmacokinetic characteristics of once-daily trospium chloride 60 mg extended-release capsules in patients with overactive bladder and in healthy subjects.

Harnett MD, Shipley J, MacLean L, Schwiderski U, Sandage BW Jr.

Clin Drug Investig. 2013 Feb;33(2):133-41. doi: 10.1007/s40261-012-0039-8.

PMID:
23203138
8.

Imidafenacin for the treatment of overactive bladder.

Leone Roberti Maggiore U, Scala C, Venturini PL, Ferrero S.

Expert Opin Pharmacother. 2013 Jul;14(10):1383-97. doi: 10.1517/14656566.2013.796930. Epub 2013 May 6. Review. Erratum in: Expert Opin Pharmacother. 2014 Feb;15(2):301.

PMID:
23641864
9.
10.

Noninvasive evaluation of brain muscarinic receptor occupancy of oxybutynin, darifenacin and imidafenacin in rats by positron emission tomography.

Yoshida A, Maruyama S, Fukumoto D, Tsukada H, Ito Y, Yamada S.

Life Sci. 2010 Jul 31;87(5-6):175-80. doi: 10.1016/j.lfs.2010.06.008. Epub 2010 Jun 18.

PMID:
20598326
11.

Effect of itraconazole on the pharmacokinetics of imidafenacin in healthy subjects.

Ohno T, Nakayama K, Nakade S, Kitagawa J, Ueda S, Miyabe H, Miyata Y, Ohnishi A.

J Clin Pharmacol. 2008 Mar;48(3):330-4. doi: 10.1177/0091270007310386. Epub 2008 Jan 24.

PMID:
18218784
12.

Muscarinic receptor binding of the novel radioligand, [3h]imidafenacin in the human bladder and parotid gland.

Yoshida A, Kuraoka S, Ito Y, Okura T, Deguchi Y, Otsuka A, Ozono S, Takeda M, Masuyama K, Araki I, Yamada S.

J Pharmacol Sci. 2014;124(1):40-6. Epub 2013 Dec 27.

13.

Effect of imidafenacin on nocturia and sleep disorder in patients with overactive bladder.

Wada N, Watanabe M, Kita M, Matsumoto S, Osanai H, Yamaguchi S, Numata A, Fujisawa M, Saga Y, Hou K, Iuchi H, Niibori D, Kura T, Taniguchi A, Kunieda M, Nakata Y, Kakizaki H.

Urol Int. 2012;89(2):215-21. doi: 10.1159/000339750. Epub 2012 Jul 25.

PMID:
22832092
14.

Long-term safety and efficacy of two different antimuscarinics, imidafenacin and solifenacin, for treatment of overactive bladder: a prospective randomized controlled study.

Yokoyama T, Koide T, Hara R, Fukumoto K, Miyaji Y, Nagai A.

Urol Int. 2013;90(2):161-7. doi: 10.1159/000345055. Epub 2012 Nov 27.

PMID:
23207959
16.

Clinical efficacy and safety of imidafenacin as add-on treatment for persistent overactive bladder symptoms despite α-blocker treatment in patients with BPH: the ADDITION study.

Takeda M, Nishizawa O, Gotoh M, Yoshida M, Takahashi S, Masumori N.

Urology. 2013 Oct;82(4):887-93. doi: 10.1016/j.urology.2013.05.008. Epub 2013 Aug 14.

PMID:
23953605
18.
19.

Immediate effect on overactive bladder symptoms following administration of imidafenacin.

Kitagawa Y, Kuribayashi M, Narimoto K, Kawaguchi S, Yaegashi H, Namiki M.

Urol Int. 2011;86(3):330-3. doi: 10.1159/000323843. Epub 2011 Feb 16.

PMID:
21325789
20.

[Pharmacological and clinical profile of imidafenacin developed as a new therapeutic agent for overactive bladder].

Uno T, Kobayashi F, Ogata A, Konomi T.

Nihon Yakurigaku Zasshi. 2008 May;131(5):379-87. Review. Japanese. No abstract available.

PMID:
18480570
Items per page

Supplemental Content

Write to the Help Desk